Tvardi Therapeutics Inc (TVRD)

$24.61 -0.60 (-2.38%)
Market Cap 235.99M
Revenue (ttm) 7.14M
Net Income (ttm) -70.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -992.58%
Debt to Equity Ratio 0.00
Volume 515,400
Avg Vol 66,974
Day's Range N/A - N/A
Shares Out 9.36M
Stochastic %K 15%
Beta 0.25
Analysts Strong Sell
Price Target $59.25

Company Profile

Tvardi Therapeutics, Inc. operates as a biotechnology company that develops medicines for cancer, chronic inflammation diseases, and fibrosis diseases. It develops inhibitors of STAT3, a molecule implicated in the initiation and progression of cancer and fibrosis. Its pipeline includes TTI-101, a small-molecule inhibitor of signal transducers and activators of transcription; and TTI-109, a STAT3 inhibitor for clinical use, including tolerability, bioavailability, and potency. Tvardi Therapeutics...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-413-1362
Address:
3 Sugar Creek Center Boulevard, Suite 525, Sugar Land, United States
lonedaddy
lonedaddy Jun. 27 at 4:22 PM
$TVRD POSner linkedin, ("The man that kept saying "there was a great unmet need for korsuva") what a joke! In our industry, we follow the science and act on the data. At Cara, we earned FDA approval for KORSUVA, an IV formulation of difelikefalin for patients on dialysis suffering from chronic pruritus. We also studied oral formulations of difelikefalin in several other potential indications, and all early- and mid-stage trials showed a positive signal. Unfortunately, pivotal studies across different indications did not show a meaningful clinical benefit versus placebo, compelling our board to look for strategic alternatives. All of this news followed a confounding commercial launch for IV KORSUVA, which faced unique dialysis market dynamics and ultimately weak government reimbursement. In the deal, we worked to maintain the possibility this drug would remain available to patients through leading dialysis providers with whom we’d secured strong relationships.
1 · Reply
lonedaddy
lonedaddy Jun. 27 at 4:16 PM
$TVRD Two big up days and this crap just tanks. Management still doesn't have the MM following it. Time for some PR and MM meetings from Conn and Alibhai.
0 · Reply
mtlewis
mtlewis Jun. 16 at 2:41 PM
$TVRD https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45913266/recently-listed-tvardi-therapeutics-lead-drug-positioned-to-drive-broad-improvement-analyst-sees-over-150-stock-upside
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 10:00 AM
Piper Sandler has updated their rating for Tvardi Therapeutics ( $TVRD ) to Overweight with a price target of 78.
0 · Reply
lonedaddy
lonedaddy Jun. 9 at 2:28 PM
$TVRD new 8K presentation. Merck ties on the BOD standout https://ir.tvarditherapeutics.com/node/14331/html
0 · Reply
Estimize
Estimize Jun. 2 at 1:01 PM
Wall St is expecting -0.84 EPS for $TVRD Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
Alex1183
Alex1183 May. 28 at 8:08 PM
$TVRD I need a price target of $800 can we get that please
1 · Reply
pulse31common
pulse31common May. 28 at 7:25 PM
$TVRD You blink, you miss. JFB doesn’t wait. 🧨
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 28 at 9:51 AM
WATCHLIST MAY 28 2025. $SPCB Supercom Bags New Electronic Monitoring Contract From Service Provider In Nebraska To Immediately Deploy Puresecurity EM Technology $ROLR High Roller Submits Internet Gaming Operator License Application In Ontario; Targets H2 2025 For Launch Of HighRoller.com Flagship Brand $MTAL Scotiabank Downgrades MAC Copper to Sector Perform, Announces $13 Price Target $IMNN Imunon shares are trading higher after the company announced it will present IMNN-001 data based on its immune biomarker analysis from its Phase 2 OVATION 2 study at ESMO Gynaecological Cancers Congress 2025 $TVRD Tvardi Therapeutics shares are trading higher after the company announced it completed the enrollment for its phase 2 clinical trial of TTI-101.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 27 at 12:08 PM
$TVRD Tvardi Therapeutics Completes Enrollment For Lead Program In Phase 2 Clinical Trial Of TTI-101 For Patients With Idiopathic Pulmonary Fibrosis
0 · Reply
Latest News on TVRD
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Jun 12, 2025, 3:07 PM EDT - 15 days ago

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

May 27, 2025, 8:00 AM EDT - 4 weeks ago

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

May 20, 2025, 8:00 AM EDT - 5 weeks ago

Tvardi Therapeutics to Participate in Upcoming Investor Conferences

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

May 13, 2025, 4:05 PM EDT - 6 weeks ago

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

May 6, 2025, 7:00 AM EDT - 7 weeks ago

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

Apr 15, 2025, 4:05 PM EDT - 2 months ago

Tvardi Therapeutics Announces Closing of Merger with Cara Therapeutics

CARA

lonedaddy
lonedaddy Jun. 27 at 4:22 PM
$TVRD POSner linkedin, ("The man that kept saying "there was a great unmet need for korsuva") what a joke! In our industry, we follow the science and act on the data. At Cara, we earned FDA approval for KORSUVA, an IV formulation of difelikefalin for patients on dialysis suffering from chronic pruritus. We also studied oral formulations of difelikefalin in several other potential indications, and all early- and mid-stage trials showed a positive signal. Unfortunately, pivotal studies across different indications did not show a meaningful clinical benefit versus placebo, compelling our board to look for strategic alternatives. All of this news followed a confounding commercial launch for IV KORSUVA, which faced unique dialysis market dynamics and ultimately weak government reimbursement. In the deal, we worked to maintain the possibility this drug would remain available to patients through leading dialysis providers with whom we’d secured strong relationships.
1 · Reply
lonedaddy
lonedaddy Jun. 27 at 4:16 PM
$TVRD Two big up days and this crap just tanks. Management still doesn't have the MM following it. Time for some PR and MM meetings from Conn and Alibhai.
0 · Reply
mtlewis
mtlewis Jun. 16 at 2:41 PM
$TVRD https://www.benzinga.com/analyst-stock-ratings/initiation/25/06/45913266/recently-listed-tvardi-therapeutics-lead-drug-positioned-to-drive-broad-improvement-analyst-sees-over-150-stock-upside
0 · Reply
JarvisFlow
JarvisFlow Jun. 12 at 10:00 AM
Piper Sandler has updated their rating for Tvardi Therapeutics ( $TVRD ) to Overweight with a price target of 78.
0 · Reply
lonedaddy
lonedaddy Jun. 9 at 2:28 PM
$TVRD new 8K presentation. Merck ties on the BOD standout https://ir.tvarditherapeutics.com/node/14331/html
0 · Reply
Estimize
Estimize Jun. 2 at 1:01 PM
Wall St is expecting -0.84 EPS for $TVRD Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
Alex1183
Alex1183 May. 28 at 8:08 PM
$TVRD I need a price target of $800 can we get that please
1 · Reply
pulse31common
pulse31common May. 28 at 7:25 PM
$TVRD You blink, you miss. JFB doesn’t wait. 🧨
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 28 at 9:51 AM
WATCHLIST MAY 28 2025. $SPCB Supercom Bags New Electronic Monitoring Contract From Service Provider In Nebraska To Immediately Deploy Puresecurity EM Technology $ROLR High Roller Submits Internet Gaming Operator License Application In Ontario; Targets H2 2025 For Launch Of HighRoller.com Flagship Brand $MTAL Scotiabank Downgrades MAC Copper to Sector Perform, Announces $13 Price Target $IMNN Imunon shares are trading higher after the company announced it will present IMNN-001 data based on its immune biomarker analysis from its Phase 2 OVATION 2 study at ESMO Gynaecological Cancers Congress 2025 $TVRD Tvardi Therapeutics shares are trading higher after the company announced it completed the enrollment for its phase 2 clinical trial of TTI-101.
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 27 at 12:08 PM
$TVRD Tvardi Therapeutics Completes Enrollment For Lead Program In Phase 2 Clinical Trial Of TTI-101 For Patients With Idiopathic Pulmonary Fibrosis
0 · Reply
Estimize
Estimize May. 26 at 6:01 PM
Wall St is expecting -0.85 EPS for $TVRD Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
lonedaddy
lonedaddy May. 23 at 4:56 PM
$TVRD I guess the bastard shorts discover this. Probably set up by Oppenheimer.
0 · Reply
mtlewis
mtlewis May. 22 at 7:48 PM
$TVRD Data presented yesterday. https://www.morningstar.com/news/business-wire/20250506124787/tvardi-therapeutics-announces-presentation-at-the-american-thoracic-society-2025-annual-conference
0 · Reply
JarvisFlow
JarvisFlow May. 21 at 3:14 PM
Oppenheimer has updated their rating for Tvardi Therapeutics ( $TVRD ) to Outperform with a price target of 65.
0 · Reply
lonedaddy
lonedaddy May. 21 at 2:46 PM
$TVRD oppenheimer PT 65: https://www.investing.com/news/analyst-ratings/oppenheimer-sets-65-target-on-tvardi-stock-with-outperform-rating-93CH-4056430
0 · Reply
Estimize
Estimize May. 20 at 10:03 PM
$TVRD reported 84.03% YoY EPS growth for Q1, in Q4. http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_content=TVRD&
0 · Reply
mtlewis
mtlewis May. 20 at 8:39 PM
$TVRD upcoming presentation. https://www.businesswire.com/news/home/20250520914596/en/
0 · Reply
mtlewis
mtlewis May. 20 at 8:38 PM
$TVRD https://www.businesswire.com/news/home/20250520914596/en/
0 · Reply
Estimize
Estimize May. 20 at 10:00 AM
$TVRD reported -3.22 EPS and 2.57 revenue for Q1. http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_content=TVRD&utm_
0 · Reply
Estimize
Estimize May. 19 at 1:03 PM
Wall St is expecting -0.95 EPS for $TVRD Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize May. 15 at 8:00 PM
Wall St is expecting -0.89 EPS for $TVRD Q2 [Reporting 08/13 AMC] http://www.estimize.com/intro/tvrd?chart=historical&metric_name=eps&utm_c
0 · Reply
mtlewis
mtlewis May. 15 at 6:48 PM
$TVRD getting attention https://www.marketscreener.com/quote/stock/TVARDI-THERAPEUTICS-INC-186765852/news/BTIG-Initiates-Tvardi-Therapeutics-at-Buy-With-55-Price-Target-49964793/
0 · Reply